Inovio Pharmaceuticals, Inc. (INO)
INO moved a median of -0.29% 30 minutes after news, and 0.00% by the close. How INO actually reacts to news — the realized, point-in-time move the market made, measured across 658 labeled events over the last three years with zero look-ahead.
INO’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 46% | 651 |
| 30-min | -0.29% | 43% | 654 |
| 60-min | 0.00% | 45% | 655 |
| to close | 0.00% | 47% | 653 |
| Middle 50% of INO reactions | -1.47% to +0.95% |
|---|---|
| Median reaction (30-min) | -0.29% |
| Measured reactions | 658 |
Half of all Inovio Pharmaceuticals, Inc. news events land between -1.47% and +0.95% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How INO reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 13 | +0.36% | 69% | +0.45% |
| Analyst downgrades | 11 | -0.41% | 36% | 0.00% |
| Coverage initiations | 22 | 0.00% | 41% | -0.09% |
| Rating reiterations | 34 | -0.13% | 44% | -0.63% |
| Price-target cuts | 10 | -0.43% | 10% | -0.86% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how INO ranks against every other measured name →
That’s how INO usually reacts — get an email when it moves on news →Email me when INO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to INO's baseline. Nothing else.
Recent INO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K INOVIO PHARMACEUTICALS, For: Oct 06 | SEC filing · Form 8-K | SEC EDGAR | +0.20% | +3.13% | |
| INOVIO to Participate in Upcoming Investor Conferences | Press release | PR Newswire | +4.47% | +1.49% | |
| Form 10-Q INOVIO PHARMACEUTICALS, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.46% | +11.12% | |
| Form 8-K INOVIO PHARMACEUTICALS, For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +3.46% | +11.12% | |
| INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | Press release | PR Newswire | +3.46% | +11.12% | |
| INOVIO to Report Second Quarter Financial Results on August 12, 2026 | Press release | PR Newswire | +1.30% | +0.88% | |
| Form 8-K INOVIO PHARMACEUTICALS, For: Jul 29 | SEC filing · Form 8-K | SEC EDGAR | +0.43% | +4.15% | |
| Form 8-K INOVIO PHARMACEUTICALS, For: Jul 29 | SEC filing · Form 8-K | SEC EDGAR | -10.95% | -10.14% | |
| INOVIO Announces Pricing of $20.0 Million Public Offering | Press release | PR Newswire | -10.95% | -10.14% | |
| INOVIO Announces Proposed Public Offering | Press release | PR Newswire | -10.95% | -10.14% | |
| Form EFFECT INOVIO PHARMACEUTICALS, | SEC filing · Form EFFECT | SEC EDGAR | +0.87% | +0.87% | |
| Form S-3 INOVIO PHARMACEUTICALS, | SEC filing · Form S-3 | SEC EDGAR | +0.33% | -4.13% | |
| INOVIO to Participate in Upcoming Scientific and Investor Conferences | Press release | PR Newswire | -0.80% | +3.17% | |
| Form S-8 INOVIO PHARMACEUTICALS, | SEC filing · Form S-8 | SEC EDGAR | -4.38% | -8.03% | |
| Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China | Press release | PR Newswire | +3.41% | +2.27% | |
| Form 8-K INOVIO PHARMACEUTICALS, For: May 19 | SEC filing · Form 8-K | SEC EDGAR | -1.20% | +6.40% | |
| Form 10-Q INOVIO PHARMACEUTICALS, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.94% | +5.43% | |
| Form 8-K INOVIO PHARMACEUTICALS, For: May 13 | SEC filing · Form 8-K | SEC EDGAR | +1.94% | +5.43% | |
| INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights | Press release | PR Newswire | +1.94% | +5.43% | |
| INOVIO to Participate in Upcoming Scientific Conferences | Press release | PR Newswire | +3.21% | +4.29% | |
| INOVIO to Report First Quarter Financial Results on May 13, 2026 | Press release | PR Newswire | +0.90% | +2.70% | |
| Lifshitz Law PLLC Announces Investigations of Inovio Pharmaceuticals, Inc. (NASDAQ: INO), Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), Oracle Corporation (NYSE: ORCL), and BlackRock, TCP Capital Corp. (NASDAQ: TCPC) | Press release | ACCESS Newswire | -0.41% | -4.13% | |
| Form DEF 14A INOVIO PHARMACEUTICALS, For: May 20 | SEC filing · Form DEF | SEC EDGAR | -2.69% | -1.80% | |
| Form 8-K INOVIO PHARMACEUTICALS, For: Apr 02 | SEC filing · Form 8-K | SEC EDGAR | -2.71% | -1.74% | |
| Inovio Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - INO | Press release | PR Newswire | -2.71% | -1.74% | |
| Form 8-K INOVIO PHARMACEUTICALS, For: Apr 01 | SEC filing · Form 8-K | SEC EDGAR | -9.63% | -16.30% | |
| INOVIO Announces Pricing of $17.5 Million Public Offering | Press release | PR Newswire | -9.63% | -16.30% | |
| INOVIO Announces Proposed Public Offering | Press release | PR Newswire | -9.63% | -16.30% | |
| INOVIO to Participate in Upcoming Scientific Conference | Press release | PR Newswire | -0.25% | -0.29% | |
| Inovio Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - INO | Press release | PR Newswire | -1.87% | +3.73% | |
| Form 10-K INOVIO PHARMACEUTICALS, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.51% | -3.49% | |
| Form 8-K INOVIO PHARMACEUTICALS, For: Mar 12 | SEC filing · Form 8-K | SEC EDGAR | +1.51% | -3.49% | |
| INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | Press release | PR Newswire | +1.51% | -3.49% | |
| INOVIO to Participate in Upcoming Scientific Conferences | Press release | PR Newswire | +0.86% | -0.57% | |
| INOVIO to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026 | Press release | PR Newswire | -0.58% | +1.75% | |
| Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM) | Press release | PR Newswire | +0.00% | +1.17% | |
| INOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM) | Press release | PR Newswire | +0.00% | +1.17% | |
| Inovio Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - INO | Press release | PR Newswire | +3.27% | +7.74% | |
| Inovio Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - INO | Press release | PR Newswire | +0.30% | +2.98% | |
| Inovio Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – INO | Press release | Business Wire | +0.62% | -2.47% | |
| INOVIO to Participate in Upcoming Scientific and Investor Conferences | Press release | PR Newswire | +0.62% | -2.47% | |
| Form 8-K INOVIO PHARMACEUTICALS, For: Jan 27 | SEC filing · Form 8-K | SEC EDGAR | +1.65% | +0.66% | |
| FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP) | Press release | PR Newswire | -2.67% | -8.95% | |
| Form 8-K INOVIO PHARMACEUTICALS, For: Dec 29 | SEC filing · Form 8-K | SEC EDGAR | -2.67% | -8.95% | |
| INOVIO Reports Inducement Grant Under Inducement Plan | Press release | PR Newswire | -0.43% | -2.60% | |
| INOVIO to Participate in December Investor Conferences | Press release | PR Newswire | -1.01% | -4.54% | |
| Form 8-K INOVIO PHARMACEUTICALS, For: Nov 11 | SEC filing · Form 8-K | SEC EDGAR | +1.75% | -2.97% | |
| INOVIO Announces Pricing of $25 Million Public Offering | Press release | PR Newswire | -3.50% | +0.00% | |
| Form 10-Q INOVIO PHARMACEUTICALS, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.50% | +0.00% | |
| Form 8-K INOVIO PHARMACEUTICALS, For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | -3.50% | +0.00% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the INO section they belong to.
Where else INO is measured.
INO earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| OPHTHOTECH CORP COMMON (OPHT) | 660 | -0.20% | 43% |
| Gritstone bio, Inc. (GRTS) | 659 | -0.01% | 50% |
| VistaGen Therapeutics, Inc. (VTGN) | 658 | +0.16% | 52% |
| Quanterix Corporation (QTRX) | 657 | -0.21% | 46% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Inovio Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled INO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 658 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 43% of INO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does INO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.